EyePoint EYPT 深 沪
等待开盘 11-10 09:30:00 美东时间
0.3619
+0.002
+0.53%
华盛通- 最 高0.3724
- 今 开0.36
- 成交量 473.49万股
- 最 低 0.344
- 昨 收 0.36
- 总市值 3120.02万
- 52周最高 19.11
- 市盈率 静 --
- 换手率 5.49%
- 52周最低 0.3305
- 委 比 -41.10%
- 总股本 8621.21万
- 历史最高 39.40
- 量 比 1.02
- 振 幅 7.89%
- 历史最低 0.3305
- 每 手 1
- 风险率 5.04%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meetings
EyePoint, Inc. will participate in several conferences and scientific meetings in November and December 2026 to discuss its innovative therapeutics for retinal diseases, including presentations on pivotal Phase 3 trial results for EYP-1901 in Wet AMD and DME. The company will present at the Guggenheim 3rd Annual Healthcare Innovation Conference, Stifel 2026 Healthcare Conference, Jefferies 2026 Global Healthcare Conference in London, and UBS Glob...
11-06 12:00
EyePoint Pharmaceuticals Inc.收跌9.9%，成交额154.65万美元
11月6日，EyePoint Pharmaceuticals Inc.（EYPT）收跌9.9%，报0.36美元，成交额154.65万美元，市值3068.29万美...
11-06 08:40
EyePoint to Report Third Quarter 2026 Financial Results on November 12, 2026
EyePoint, Inc. (Nasdaq: EYPT) will host a conference call on November 12, 2026, at 8:30 a.m. ET to discuss its Q3 2026 financial results and recent developments. The call will be accessible via a live webcast on the Company's website, with a replay available afterward. EyePoint focuses on developing innovative therapeutics for retinal diseases, with its lead product, DURAVYU™, in Phase 3 trials for diabetic macular edema. The company is headquart...
11-05 12:00
EyePoint Pharmaceuticals Inc.收涨6.7%，成交额138.76万美元
11月4日，EyePoint Pharmaceuticals Inc.（EYPT）收涨6.7%，报0.4美元，成交额138.76万美元，市值3447.59万美元...
11-04 08:33
药物受理最新动态：Alimera Sciences, Inc.氟轻松玻璃体内植入剂进口再注册申请获受理
国家药品监督管理局药品审评中心数据显示，2026年11月3日，Alimera Sciences, Inc.的氟轻松玻璃体内植入剂申请已获受理，受理号为JYHZ...
11-03 19:15
医药行业10月裁员统计：裁员率最高达94%
进入年底，医药行业裁员消息密集释放。从跨国药企的全球降本计划，到 Biotech 因临床、商业化不及预期被动缩编，一起来看看本月行业裁员事件汇总。 10 月 ...
10-30 17:06
EyePoint Pharmaceuticals Inc.收跌0.68%，成交额356.71万美元
10月28日，EyePoint Pharmaceuticals Inc.（EYPT）收跌0.68%，报0.36美元，成交额356.71万美元，市值3131.2...
10-28 07:38
美股大行评级 | 潜在涨幅203.03%！BTIG上调Rapport Therapeutics目标价至89美元，维持"买入"评级
今日重点评级关注：BTIG：维持Rapport Therapeutics"买入"评级，目标价从75美元升至89美元；摩根士丹利：维持希捷科技"超配"评级，目标价从1187美元升至1200美元
10-21 12:30
